演題抄録

臓器別シンポジウム

開催概要
開催回
第56回・2018年・横浜
 

転移性脳腫瘍治療のエビデンス・ガイドライン

演題番号 : SY16-1

[筆頭演者]
演者)園田 順彦:1 

1:山形大学・脳神経外科

 

The guidelines for management of metastatic brain tumors was published in 2016 and was minor revised in 2018. Whole brain radiation is still standard therapy for all brain metastasis (Grade A or B) (Aoyama et al. JAMA 2015, Mulvenna et al. Lancet 2016). However, recently some RCT trials were published regarding to the usefulness of stereotactic radiosurgery (SRS) or radiotherapy (SRT) for 2-4 small metastatic brain tumors as well as small single lesion (Sahgal et al. Int J Radiat Oncol Biol Phys 2015, Brown et al. Lancet Oncol. 2017, Kayama et al. J Clin. Oncol in press). Therefore, recommendation of stereotactic irradiation (STI) of the treatment for 1-4 metastatic brain tumors will be changed from Grade C1 to Grade B in the revised edition. Similarly, although there was no recommendation of SRS or SRT for multiple (over 4 lesions) metastatic brain tumors, new recommendation regarding to STI (Grade C1) will be described in the revised guideline (Yamamoto et al. Lancet Oncol, 2014). Recommendation for chemotherapy including molecular targeted agents was still Grade C1 and will not change in the revised edition.

前へ戻る